Psoriatic arthritis: new US guidelines put biologics first-line

Guidance also given on patients with comorbidities

For the first time, US guidelines are recommending treatment-naive patients with psoriatic arthritis be prescribed a tumour necrosis factor alpha (TNF-alpha) inhibitor as first-line treatment.

TNF-alpha inhibitors are the first-choice treatment for treatment-naive patients and for patients failing to respond to other therapies, unless there are contraindications, in the guidelines issued on 30 November by the American College of Rheumatology and the National Psoriasis Foundation.

They are preferred over the oral small molecule drugs: methotrexate; sulfasalazine;